122 related articles for article (PubMed ID: 38753354)
1. AEL transformed from post-ET myelofibrosis with a sinusoidal pattern, JAK2 mutation, and biallelic TP53 inactivation.
Wei Q; You MJ
Blood; 2024 May; 143(20):2107. PubMed ID: 38753354
[No Abstract] [Full Text] [Related]
2. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
[TBL] [Abstract][Full Text] [Related]
3. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
4. Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis.
Mora B; Siracusa C; Rumi E; Maffioli M; Casetti IC; Barraco D; Merli M; Rossi M; Ubezio M; Accetta R; Libera L; Pietra D; Trotti C; Uccella S; Pallotti F; Casalone R; Bertù L; Arcaini L; Della Porta MG; Passamonti F
Leukemia; 2021 May; 35(5):1490-1493. PubMed ID: 33051550
[No Abstract] [Full Text] [Related]
5. Comparison of JAK2
Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
[TBL] [Abstract][Full Text] [Related]
6. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
7. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations and polymorphisms in primary myelofibrosis.
Raza S; Viswanatha D; Frederick L; Lasho T; Finke C; Knudson R; Ketterling R; Pardanani A; Tefferi A
Am J Hematol; 2012 Feb; 87(2):204-6. PubMed ID: 22052707
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
Fraga GR; Caughron SK
Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
[TBL] [Abstract][Full Text] [Related]
10. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
Pasqualucci L; Li S; Meloni G; Schnittger S; Gattenlohner S; Liso A; Di Ianni M; Martelli MP; Pescarmona E; Foa R; Haferlach T; Skoda RC; Falini B
Leukemia; 2008 Jul; 22(7):1459-63. PubMed ID: 18200037
[No Abstract] [Full Text] [Related]
11. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Ohyashiki K; Ohyashiki JH
Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
[No Abstract] [Full Text] [Related]
12. Progression of
Holmström MO; Novotny GW; Petersen J; Aaboe-Jørgensen M; Hasselbalch HC; Andersen MH; Nielsen SL; Fassi DE; Schöllkopf C
Leuk Lymphoma; 2019 Dec; 60(13):3296-3299. PubMed ID: 31256699
[No Abstract] [Full Text] [Related]
13. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
14. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
[No Abstract] [Full Text] [Related]
15. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
16. The emergence of a JAK2 V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis.
Zhong B; Medeiros LJ; Wang W
Br J Haematol; 2019 Aug; 186(3):396. PubMed ID: 31134612
[No Abstract] [Full Text] [Related]
17. An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.
Maia RC; Bonamino MH; Robaina MC; Amaral N; Bonecker S; Zalcberg IR; Klumb CE
Blood Cells Mol Dis; 2015 Dec; 55(4):347-50. PubMed ID: 26460258
[TBL] [Abstract][Full Text] [Related]
18. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.
Guglielmelli P; Biamonte F; Spolverini A; Pieri L; Isgrò A; Antonioli E; Pancrazzi A; Bosi A; Barosi G; Vannucchi AM
Leukemia; 2010 Aug; 24(8):1533-7. PubMed ID: 20520633
[No Abstract] [Full Text] [Related]
19. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]